Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF IV
At a glance
Conditions
NCT05236556
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
UMass Chan Medical School
Worcester, Massachusettsno site contact published
University of Florida College of Medicine - Jacksonville
Jacksonville, Floridano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Alok Kapoor, MD · PRINCIPAL_INVESTIGATOR · UMass Chan Medical School
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Initiation of Oral Anticoagulation (AC) Use12 months
The number of participants who initiate AC will be measured using the first encounter for each participant in the 12 months after randomization of providers and launch of the enhanced alert. To count as an AC initiation, a participant will have to have presence of an anticoagulant on his/her current medication list or an international normalized ratio (INR) lab value 1.5 or greater in the two months following the index encounter.
- Length of Duration for Oral Anticoagulation (AC) Use12 months
The number of days participants continue on AC for one year after AC initiation will be tracked. Up to one month off AC such as for bleeding or surgical procedure will be permitted so long as the participant resumes AC prior to the end of the 12 month follow up.